{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Disease+Modifying+therapy", "query": { "intervention": "Disease Modifying therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 186, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Disease+Modifying+therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-07T18:05:31.520Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04134728", "title": "Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "GSK3196165 (Otilimab)", "type": "BIOLOGICAL" }, { "name": "Sarilumab", "type": "BIOLOGICAL" }, { "name": "Placebo to GSK3196165/ Sarilumab", "type": "DRUG" }, { "name": "csDMARDs", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2019-10-31", "completion_date": "2022-02-01", "has_results": true, "last_update_posted_date": "2023-07-17", "last_synced_at": "2026-09-07T18:05:31.520Z", "location_count": 46, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04134728" }, { "nct_id": "NCT02873936", "title": "Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Filgotinib", "type": "DRUG" }, { "name": "Placebo to match filgotinib", "type": "DRUG" }, { "name": "csDMARDs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 449, "start_date": "2016-07-27", "completion_date": "2018-06-26", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-09-07T18:05:31.520Z", "location_count": 55, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Hemet", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02873936" }, { "nct_id": "NCT02878798", "title": "Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome" ], "interventions": [ { "name": "topiramate", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 132, "start_date": "2018-02-12", "completion_date": "2021-09-28", "has_results": true, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-09-07T18:05:31.520Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Orange, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02878798" }, { "nct_id": "NCT04623242", "title": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alzheimers Disease", "Dementia", "Alzheimers Disease, Familial" ], "interventions": [ { "name": "Gantenerumab", "type": "DRUG" }, { "name": "Solanezumab", "type": "DRUG" }, { "name": "Matching Placebo (Gantenerumab)", "type": "DRUG" }, { "name": "Matching Placebo (Solanezumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 194, "start_date": "2012-12", "completion_date": "2020-03-06", "has_results": true, "last_update_posted_date": "2022-09-22", "last_synced_at": "2026-09-07T18:05:31.520Z", "location_count": 10, "location_summary": "Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04623242" }, { "nct_id": "NCT01573546", "title": "ENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cognitive Impairment, no Dementia (CIND)" ], "interventions": [ { "name": "Aerobic Exercise", "type": "BEHAVIORAL" }, { "name": "DASH diet", "type": "BEHAVIORAL" }, { "name": "Health education control", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 160, "start_date": "2011-12", "completion_date": "2018-03", "has_results": false, "last_update_posted_date": "2018-04-18", "last_synced_at": "2026-09-07T18:05:31.520Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01573546" }, { "nct_id": "NCT01721057", "title": "A Study in Moderate to Severe Rheumatoid Arthritis Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "cDMARD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 684, "start_date": "2012-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-09-07T18:05:31.520Z", "location_count": 48, "location_summary": "Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 45 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721057" }, { "nct_id": "NCT05407805", "title": "A Study to Learn About Sickle Cell Disease In Adult Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Electronic Diary", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2022-02-10", "completion_date": "2024-06-24", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-09-07T18:05:31.520Z", "location_count": 4, "location_summary": "Hollywood, Florida • Upper Marlboro, Maryland • Waltham, Massachusetts + 1 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Upper Marlboro", "state": "Maryland" }, { "city": "Waltham", "state": "Massachusetts" }, { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05407805" }, { "nct_id": "NCT03369405", "title": "Thyroid Disease and Chronic Periodontitis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Thyroid Diseases", "Chronic Periodontitis" ], "interventions": [ { "name": "NO intervention, patient records review only", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 4965, "start_date": "2018-02-02", "completion_date": "2023-09-01", "has_results": false, "last_update_posted_date": "2023-10-02", "last_synced_at": "2026-09-07T18:05:31.520Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03369405" }, { "nct_id": "NCT05688436", "title": "A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Diroximel Fumarate", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "BIOLOGICAL" }, { "name": "Fingolimod", "type": "DRUG" }, { "name": "Glatiramer acetate", "type": "DRUG" }, { "name": "Interferon beta", "type": "BIOLOGICAL" }, { "name": "Natalizumab", "type": "BIOLOGICAL" }, { "name": "Ocrelizumab", "type": "BIOLOGICAL" }, { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Ozanimod", "type": "DRUG" }, { "name": "Peginterferon beta-1a", "type": "BIOLOGICAL" }, { "name": "Ponesimod", "type": "DRUG" }, { "name": "Siponimod", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 1178, "start_date": "2021-09-24", "completion_date": "2031-01-17", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-07T18:05:31.520Z", "location_count": 1, "location_summary": "Eden Prairie, Minnesota", "locations": [ { "city": "Eden Prairie", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05688436" }, { "nct_id": "NCT04956744", "title": "A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "IMS001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ImStem Biotechnology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2021-08-31", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-09-07T18:05:31.520Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Worcester, Massachusetts • Salt Lake City, Utah", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04956744" } ] }